Eldelumab

Eldelumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It was developed by MedImmune, a subsidiary of AstraZeneca. Eldelumab works by targeting and inhibiting the interleukin-7 receptor, a protein that plays a crucial role in the immune response.

Mechanism of Action

Eldelumab is a monoclonal antibody that binds to the interleukin-7 receptor (IL-7R). The IL-7R is a protein found on the surface of certain immune cells, including T cells and B cells. By binding to this receptor, eldelumab prevents the binding of interleukin-7, a cytokine that promotes the survival and proliferation of these immune cells. This inhibition reduces the immune response, which can be beneficial in the treatment of autoimmune diseases.

Clinical Trials

Eldelumab has been tested in several clinical trials for its efficacy in treating various autoimmune diseases. In a Phase II trial for moderate to severe ulcerative colitis, eldelumab showed a significant reduction in disease activity compared to placebo. However, further studies are needed to confirm these results and determine the optimal dosing regimen.

Side Effects

As with all medications, eldelumab can cause side effects. The most common side effects reported in clinical trials include nausea, headache, and fatigue. Serious side effects can include infections due to the suppression of the immune system. Patients should discuss potential side effects with their healthcare provider before starting treatment with eldelumab.

See Also

• Monoclonal antibodies
• Autoimmune diseases
• Interleukin-7 receptor
• Clinical trials